title: [Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies].
abstract: Glatiramer acetate (GA, Copaxone), a standardized mixture of synthetic polypeptides, has now been approved also in Germany for the treatment of relapsing-remitting multiple sclerosis (RR-MS). After it had been shown effective in suppression of experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), it was evaluated in several clinical studies. In these studies, GA could alter the natural history of MS by both reducing the relapse rate and affecting disability. The clinical therapeutic effect of GA was consistent with the effect on magnetic resonance imaging-defined disease activity and burden in a recent multicenter study. As a daily standard dose, 20 mg of GA is injected subcutaneously. The induction of GA-reactive T-helper 2-like regulatory suppressor cells is thought to be the main mechanism of action. The most common adverse effects are mild injection site reactions. A remarkable but rare adverse effect is the only transient immediate post-injection systemic reaction manifested by flushing, chest tightness, palpitations, and dyspnea. Antibodies to GA which are induced during GA treatment do not interfere with its clinical effects.
authors.affiliation: Abteilung für Neuroimmunologie, Max-Planck-Institut für Neurobiologie, Martinsried.
authors.forename: T
authors.initials: T
authors.lastname: Ziemssen
authors.forename: O
authors.initials: O
authors.lastname: Neuhaus
authors.forename: C
authors.initials: C
authors.lastname: Farina
authors.forename: H P
authors.initials: HP
authors.lastname: Hartung
authors.forename: R
authors.initials: R
authors.lastname: Hohlfeld
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D000068717:Glatiramer Acetate; D006801:Humans; D007279:Injections, Subcutaneous; D015337:Multicenter Studies as Topic; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D010455:Peptides; D000068717:Glatiramer Acetate